Betta Pharmaceuticals

plan B fail reroute road path trail miss

Biotech

C4 culls phase 1/2 cancer program after efficacy fail

C4 Therapeutics is discontinuing one of its cancer assets after a phase 1/2 trial proved the drug ineffective.

Gabrielle Masson Nov 1, 2023 11:29am

betta fish swim fish

C4 joins Betta's tank to bring lung cancer drug to greater China

May 30, 2023 9:20am